NASDAQ:HROWHarrow Health Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Harrow Health Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.31 +0.61 (+12.98 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$4.70Now: $5.31▼$5.3350-Day Range$3.61MA: $4.41▼$5.3152-Week Range$3.33Now: $5.31▼$8.99Volume143,400 shsAverage Volume117,602 shsMarket Capitalization$136.04 millionP/E RatioN/ADividend YieldN/ABeta0.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Harrow Health has a potential upside of 135.4% from its current price of $5.31.Amount of Analyst CoverageHarrow Health has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesHarrow Health has received 60 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHarrow Health has received 82 “underperform” votes. (Add your “underperform” vote.)Community SentimentHarrow Health has received 57.75% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Harrow Health and other stocks. Vote “Outperform” if you believe HROW will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HROW will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $144,264.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.64% of the stock of Harrow Health is held by insiders.Percentage Held by Institutions38.90% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow in the coming year, from ($0.47) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.05 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HROW Previous Symbol CUSIPN/A CIKN/A Webwww.harrowinc.com Phone615-733-4730Debt Debt-to-Equity Ratio1.19 Current Ratio1.95 Quick Ratio1.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$51.17 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book9.00Profitability EPS (Most Recent Fiscal Year)($0.29) Net Income$170,000.00 Net Margins-47.54% Return on Equity-32.90% Return on Assets-14.74%Miscellaneous EmployeesN/A Outstanding Shares25,620,000Market Cap$136.04 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable NASDAQ:HROW Rates by TradingView Receive HROW News and Ratings via Email Sign-up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Harrow Health (NASDAQ:HROW) Frequently Asked Questions How has Harrow Health's stock been impacted by COVID-19 (Coronavirus)? Harrow Health's stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HROW shares have increased by 11.6% and is now trading at $5.31. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Harrow Health? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harrow Health. When is Harrow Health's next earnings date? Harrow Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Harrow Health. How were Harrow Health's earnings last quarter? Harrow Health (NASDAQ:HROW) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.45. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.14 million. Harrow Health had a negative net margin of 47.54% and a negative return on equity of 32.90%. View Harrow Health's earnings history. What price target have analysts set for HROW? 2 analysts have issued 12 month target prices for Harrow Health's shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Harrow Health's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price. View analysts' price targets for Harrow Health. Has Harrow Health been receiving favorable news coverage? Media stories about HROW stock have trended extremely positive on Wednesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Harrow Health earned a news impact score of 5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutHarrow Health. Are investors shorting Harrow Health? Harrow Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,390,000 shares, an increase of 13.0% from the April 30th total of 1,230,000 shares. Based on an average daily volume of 176,500 shares, the short-interest ratio is presently 7.9 days. Currently, 5.9% of the company's stock are sold short. View Harrow Health's Current Options Chain. Who are some of Harrow Health's key competitors? Some companies that are related to Harrow Health include AnaptysBio (ANAB), Clovis Oncology (CLVS), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Trillium Therapeutics (TRIL), Passage Bio (KROS), Xenon Pharmaceuticals (XENE), Atreca (BCEL), NewLink Genetics (NLNK), AC Immune (ACIU), BioDelivery Sciences International (BDSI), Neoleukin Therapeutics (NLTX), DURECT (DRRX), Vectura Group (VEGPF) and Beyondspring (BYSI). View all competitors. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include Corbus Pharmaceuticals (CRBP), Mustang Bio (MBIO), QuickLogic (QUIK), Amarin (AMRN), Canopy Growth (CGC), Crispr Therapeutics (CRSP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Adamis Pharmaceuticals (ADMP) and Agile Therapeutics (AGRX). Who are Harrow Health's key executives? Harrow Health's management team includes the following people: Mr. Mark L. Baum, Founder, CEO & Director (Age 46)Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 37)Mr. John P. Saharek, Chief Commercial Officer (Age 59)Mr. David Moufarrège, VP of TechnologyMr. Pramod Sharma Ph.D., VP of Quality What is Harrow Health's stock symbol? Harrow Health trades on the NASDAQ under the ticker symbol "HROW." Who are Harrow Health's major shareholders? Harrow Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.42%), BlackRock Inc. (1.83%), Cadence Capital Management LLC (0.90%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.48%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Harrow Health stock include Opaleye Management Inc and Robert J Kammer. View institutional ownership trends for Harrow Health. Which major investors are selling Harrow Health stock? HROW stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Squarepoint Ops LLC, Morgan Stanley, Acadian Asset Management LLC, Russell Investments Group Ltd., Cadence Capital Management LLC, Geode Capital Management LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Harrow Health. Which major investors are buying Harrow Health stock? HROW stock was bought by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., Jane Street Group LLC, Advisor Group Holdings Inc., Citigroup Inc., Wells Fargo & Company MN, and BlackRock Inc.. View insider buying and selling activity for Harrow Health. How do I buy shares of Harrow Health? Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Harrow Health's stock price today? One share of HROW stock can currently be purchased for approximately $5.31. How big of a company is Harrow Health? Harrow Health has a market capitalization of $136.04 million and generates $51.17 million in revenue each year. The company earns $170,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. What is Harrow Health's official website? The official website for Harrow Health is www.harrowinc.com. How can I contact Harrow Health? Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at 615-733-4730 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
